China’s Nanjing King-Friend Biochemical Pharmaceutical is paying $95m to increase its share in US generic injectables specialist Meitheal Pharmaceuticals to a majority stake, the two companies have announced.
China’s Nanjing King-Friend Takes Control Of US Injectables Specialist Meitheal
China’s Nanjing King-Friend Biochemical Pharmaceutical has taken a majority stake in US generic injectables specialist Meitheal Pharmaceuticals.
